

10/593133


WO 2005/090313

PCT/IB2005/000597

142

CLAIMS

1. A compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



EPO - DG 1

19. 01. 2006

(100)

wherein:

- 10  $R^1$  represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy,  $C_{1-6}$  alkanoyl,  $C_{1-6}$  haloalkanoyl,  $-S(O)_n C_{1-6}$  alkyl,  $-S(O)_n C_{1-6}$  haloalkyl and pentafluorothio;
- 15  $R^2$  represents ~~hydrogen~~, halo, cyano, nitro,  ~~$C_{1-6}$  alkyl~~,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $C_{2-6}$  alkynyl,  $C_{2-6}$  haloalkynyl,  $-S(O)_n C_{1-6}$  alkyl,  $-S(O)_n C_{1-6}$  haloalkyl,  $-(C_{0-3}$  alkylene)- $C_{3-8}$  cycloalkyl,  $C_{1-6}$  alkanoyl, optionally substituted by  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkanoyl, optionally substituted by  $C_{1-6}$  alkoxy, phenyl, het,  $-(C_{0-3}$  alkylene)- $N(R^a)R^b$ ,  $-(C_{0-3}$  alkylene)- $C(O)NR^aR^b$  or  $-(C_{0-3}$  alkylene)- $N(R^c)C(O)R^d$ ;
- 20  $R^3$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $-(C_{0-3}$  alkylene)- $C_{3-8}$  cycloalkyl,  $-(C_{1-3}$  alkylene)- $S(O)_n C_{1-6}$  alkyl,  $-(C_{1-3}$  alkylene)- $S(O)_n C_{1-6}$  haloalkyl,  $-(C_{0-3}$  alkylene)- $N(R^a)R^b$ ,  $-(C_{0-3}$  alkylene)-phenyl,  $-(C_{0-3}$  alkylene)-het,  $-(C_{2-3}$  alkenylene)-phenyl,  $-(C_{2-3}$  alkenylene)-het,  $C_{1-6}$  alkanoyl,  $C_{1-6}$  haloalkanoyl or  $-N(R^c)CO_2R^d$ ;
- 25  $R^4$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $-(C_{0-3}$  alkylene)- $R^7$  or  $-(C_{1-3}$  alkylene)- $R^8$ ;

- or  $R^3$  and  $R^4$  taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;

BEST AVAILABLE COPY

WO 2005/090313

PCT/IB2005/000597

143

$R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy,  $-N=C(R^{10})(C_{0-5}\text{alkylene})-R^{11}$  or  $-N(R^{12})R^{13}$ ;

5  $R^6$  represents  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

$R^7$  represents  $C_{3-8}$ cycloalkyl,  $-S(O)_nR^9$ , phenyl, het,  $-CO_2R^6$  or  $C(O)N(R^a)R^b$ ;

$R^8$  represents hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy, cyano,  $-N(R^a)R^b$  or  $-O-C(O)R^6$ ;

10

$R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}$ cycloalkyl,  $-N(R^a)R^b$ , phenyl or het;

$R^{10}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

15  $R^{11}$  represents hydrogen, hydroxy,  $C_{1-3}$ alkoxy,  $-N(R^a)R^b$ , phenyl, het or  $C_{3-8}$ cycloalkyl, with the proviso that  $-N=C(R^{10})(C_{0-5}\text{alkylene})-R^{11}$  is not  $-N=CH_2$ ;

$R^{12}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl or  $C_{1-6}$  haloalkenyl;

20  $R^{13}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl,  $C_{1-6}$  haloalkenyl  $C_{3-8}$ cycloalkyl, phenyl, het,  $-(C_{1-6}\text{alkylene})-R^{14}$ ,  $-C(O)_pR^{15}$  or  $-CON(R^{16})(C_{1-6}\text{alkylene})-R^{17}$ ;

$R^{14}$  represents hydroxy,  $C_{1-3}$ alkoxy,  $C_{1-3}$ haloalkoxy,  $C_{3-8}$ cycloalkyl, phenyl, het or  $-N(R^a)R^b$ ;

25

$R^{15}$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl or  $-(C_{1-6}\text{alkylene})-C_{1-3}$ alkoxy;

$R^{16}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

30  $R^{17}$  represents hydrogen or  $N(R^a)R^b$ ;

$R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents  $-(C_{0-3}\text{alkylene})-C_{3-8}$  cycloalkyl,  $-(C_{0-3}\text{alkylene})$ -phenyl or  $-(C_{0-3}\text{alkylene})$ -het, or together  $R^a$  and  $R^b$  form a 4- to 7-

WO 2005/090313

PCT/IB2005/000597

144

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub> haloalkoxy;

R<sup>c</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub> alkylene)-C<sub>3-6</sub> cycloalkyl, -(C<sub>0-3</sub> alkylene)-phenyl or -(C<sub>0-3</sub> alkylene)-het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

15 where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, C<sub>1-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkoxy carbonyl and NR<sup>a</sup>R<sup>b</sup>;

25 where C<sub>3-6</sub> cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl, hydroxy, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub> haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

30

2. A compound according to claim 1, wherein R<sup>1</sup> is a phenyl group which bears chloro substituents at the 2- and 6-positions, and a substituent at the 4-position selected from trifluoromethyl, difluoromethoxy, trifluoromethoxy, trifluoromethylthio and pentafluorothio.

WO 2005/090313

PCT/IB2005/000597

145

3. A compound according to claim 1 or 2, wherein  $R^2$  is selected from ~~hydrogen~~ cyano,  $C_{1-6}$  haloalkyl,  $C_{3-8}$  cycloalkyl, e.g. cyclopropyl,  $C_{1-6}$  alkanoyl and  $-C(O)N(R^a)R^b$ .

5 4. A compound according to claim 3, wherein  $R^2$  is cyano.

5. A compound according to any one of claims 1-4, wherein  $R^3$  is selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}$  cycloalkyl,  $-(C_{1-3}\text{alkylene})-S(O)_n C_{1-6}\text{alkyl}$ ,  $-N(R^a)R^b$ ,  $C_{1-6}$  alkanoyl,  $-N(R^a)CO_2R^6$ , phenyl, optionally substituted by one or more halo, and benzyl.

10

6. A compound according to claim 5, wherein  $R^3$  is methyl.

7. A compound according to any one of claims 1-6, wherein  $R^4$  is selected from hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $-(C_{0-3}\text{alkylene})-C_{3-8}$  cycloalkyl, cyanomethyl, 2-  
15 hydroxyethyl,  $-(C_{1-2}\text{alkylene})\text{-het}$ ,  $-(C_{0-3}\text{alkylene})\text{-phenyl}$ ,  $-(C_{0-1}\text{alkylene})-S(O)_n R^8$ ,  $-(C_{1-3}\text{alkylene})-O-C(O)R^8$ ,  $-(C_{1-3}\text{alkylene})-C(O)N(R^a)R^b$  and  $-CO_2R^8$ .

8. A compound according to claim 7, wherein  $R^4$  is selected from hydrogen, methyl, ethyl, trifluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, methylsulfonyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, aminosulfonyl, N,N-  
20 dimethylaminosulfonyl, methylsulfonylmethyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, 1-(trifluoromethyl)cyclopropylmethyl, cyanomethyl, methoxycarbonyl, triazolethyl, pyrimidin-4-ylmethyl, 1,2,4-oxadiazol-3-ylmethyl, pyrazol-3-ylmethyl, 1-methyl-1H-imidazol-2-yl, 5-methyl-isoaxazol-3-ylmethyl, 2-pyridin-4-ylethyl, aminocarbonylmethyl,  
25 benzyl and 4-fluorobenzyl.

9. A compound according to any one of claims 1-8, wherein  $R^5$  is selected from hydrogen, halo,  $C_{1-6}$  alkoxy,  $-N=C(H)R^{11}$ , where  $R^{11}$  is ethoxy, N,N-dimethyl or phenyl, and  $-NR^{12}R^{13}$ .

30

10. A compound according to claim 9, wherein  $R^5$  is amino.

11. A compound of formula (I) selected from:

WO 2005/090313

PCT/IB2005/000597

146

- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2,2-difluoroethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-1,1,1-trifluoro-*N*-methylmethanesulfonamide;
- 5 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-3,4-difluorobenzenesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(cyclopropylmethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-
- 10 (cyanomethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(pyridin-2-ylmethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-benzylmethanesulfonamide;
- 15 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(2-(dimethylamino)ethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-1-(methylsulfonyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(2-
- 20 hydroxyethyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-[(methylthio)methyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)cyclopropanesulfonamide;
- 25 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-[(dimethylamino)sulfonyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-
- 30 yl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-1-phenylmethanesulfonamide;
- (*E*)-*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-2-phenylethylsulfonamide;

WO 2005/090313

PCT/IB2005/000597

147

- N-[5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;
- 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-(1,1-dioxidoisothiazolidin-2-yl)-1H-pyrazole-3-carbonitrile;
- 5 N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-methylmethanesulfonamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(cyclopropylmethyl)-1,1,1-trifluoromethanesulfonamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)methanesulfonamide;
- 10 N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-(methylsulfonyl)methanesulfonamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-cyclobutyl-1,1,1-trifluoromethanesulfonamide;
- 15 N-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;
- N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1,1,1-trifluoro-N-methylmethanesulfonamide;
- N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;
- 20 N-[3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;
- N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl)methanesulfonamide;
- 25 N-[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)methanesulfonamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)methanesulfonamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazol-4-yl]-N-[2-(1H-30 1,2,4-triazol-1-yl)ethyl]methanesulfonamide;
- 5-amino-4-[bis(methylsulfonyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1H-pyrazole-3-carboxamide;
- N-[5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-N-(methylsulfonyl)methanesulfonamide;

WO 2005/090313

PCT/IB2005/000597

148

*N*-[3-acetyl-5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(methylsulfonyl)methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-(difluoromethoxy)phenyl]-1*H*-pyrazol-4-yl]-*N*-(methylsulfonyl)methanesulfonamide;

5 *N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-[(1-(trifluoromethyl)cyclopropyl)methyl]methanesulfonamide;

10 *N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(methylsulfonyl)ethanesulfonamide;

methyl 5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl(methylsulfonyl)carbamate;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-methylmethanesulfonamide;

15 *N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(2-fluoroethyl)methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(1,2,4-oxadiazol-3-ylmethyl)methanesulfonamide;

20 *N*<sup>2</sup>-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*<sup>2</sup>-(methylsulfonyl)glycinamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(1*H*-pyrazol-3-ylmethyl)methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(2,2,3,3,3-pentafluoropropyl)methanesulfonamide;

25 *N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(2-pyrrolidin-1-ylethyl)methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-(2-morpholin-4-ylethyl)methanesulfonamide;

30 *N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-[(1-methyl-1*H*-imidazol-2-yl)methyl]methanesulfonamide;

*N*-[5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl]-*N*-[(5-methylisoxazol-3-yl)methyl]methanesulfonamide;

[(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)(methylsulfonyl)amino]methyl pivalate;

WO 2005/090313

PCT/IB2005/000597

149

- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-ethylmethanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-benzylmethanesulfonamide;
- 5 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(4-fluorobenzyl)methanesulfonamide;
- N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-1-(methylsulfonyl)ethanesulfonamide;
- N*-(5-amino-1-[2-chloro-4-pentafluorothio-phenyl]-3-cyano-1*H*-pyrazol-4-yl)-*N*-
- 10 (methylsulfonyl)methanesulfonamide;
- 5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-(1,1-dioxido-1,2-thiazinan-2-yl)-1*H*-pyrazole-3-carbonitrile;
- N*-(5-(benzylamino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;
- 15 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-yl)-2-methoxyacetamide;
- ethyl 4-[bis(methylsulfonyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-5-ylimidoformate;
- N*-(3-cyano-5-[(cyclopropylmethyl)amino]-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-
- 20 pyrazol-4-yl)methanesulfonamide;
- N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-yl)acetamide;
- N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-methoxy-1*H*-pyrazol-4-yl)methanesulfonamide;
- 25 *N*-(3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-(methylamino)-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;
- N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[[(dimethylamino)methylene]amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;
- 30 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[[2-(dimethylamino)ethyl]amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;
- N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-pyrrolidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;



WO 2005/090313

PCT/IB2005/000597

150

*N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-morpholin-4-ylethyl)amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;

*N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;

5 *N*-(5-amino-3-cyclopropyl-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;

~~*N*-(5-amino-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)methanesulfonamide;~~

10 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(pyridin-4-ylmethyl)amino]-1*H*-pyrazol-4-yl)methanesulfonamide;

*tert*-butyl ((5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)amino)sulfonylcarbamate;

*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2-pyridin-4-ylethyl)methanesulfonamide;

15 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(pyrazin-2-ylmethyl)methanesulfonamide;

*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-[(6-aminopyridin-3-yl)methyl]methanesulfonamide;

20 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-2-oxo-*N*-(2,2,2-trifluoroethyl)propane-1-sulfonamide;

*N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(3-(dimethylamino)propyl)amino]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

25 *N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2-piperidin-1-ylethyl)amino]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)sulfamide;

*N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-4-fluoro-*N*-(methylsulfonyl)benzenesulfonamide;

30 *N*-(5-amino-3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1*H*-pyrazol-4-yl)-2,4-difluoro-*N*-(methylsulfonyl)benzenesulfonamide;

methyl 3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-4-[(methylsulfonyl)(2,2,2-trifluoroethyl)amino]-1*H*-pyrazol-5-ylcarbamate;

*N*-(5-(((2-aminoethyl)amino)carbonyl)amino)-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;

WO 2005/090313

PCT/IB2005/000597

151

- trifluoroacetate salt of *N*-(5-[(2-azetidin-1-ylethyl)amino]-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;  
*N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(2,4-dihydroxyphenyl)methylene]amino)-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide;  
5 *N*-(5-chloro-3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-1*H*-pyrazol-4-yl)-*N*-(2,2,2-trifluoroethyl)methanesulfonamide; or  
*N*-(3-cyano-1-[2,6-dichloro-4-pentafluorothiophenyl]-5-[(3-(dimethylamino)ethyl)amino]-1*H*-pyrazol-4-yl)-*N*-(methylsulfonyl)methanesulfonamide;  
10 or a pharmaceutically acceptable salt or solvate thereof.

12. A pharmaceutical or veterinary composition comprising a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, and a suitable excipient or carrier.

15

13. A compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, for use in medical therapy.

- ~~14. Use of a compound according to any one of claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof, in the manufacture of a human or animal parasitocidal medicament.~~

- ~~15. A method of treating a human or animal parasitic infection comprising administration of a therapeutically acceptable amount of compound according to any one claims 1-11, or a pharmacologically or veterinarily acceptable salt or solvate thereof.~~

~~W/O 2005/090313~~


152

142

~~PCT/IB2005/000597~~

14. Use of a compound of formula (I) ~~CLAIMS~~

1. ~~A compound of formula (I)~~ (or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



wherein:

- 10 R<sup>1</sup> represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, -S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl and pentafluorothio;
- 15 R<sup>2</sup> represents hydrogen, halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, C<sub>2-6</sub> alkynyl, C<sub>2-6</sub> haloalkynyl, -S(O)<sub>n</sub>C<sub>1-6</sub> alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-8</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, phenyl, het, -(C<sub>0-3</sub>alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub>alkylene)-C(O)NR<sup>a</sup>R<sup>b</sup> or -(C<sub>0-3</sub>alkylene)-N(R<sup>c</sup>)C(O)R<sup>d</sup>;
- 20 R<sup>3</sup> represents C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-8</sub> cycloalkyl, -(C<sub>1-3</sub>alkylene)-S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -(C<sub>1-3</sub>alkylene)-S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub>alkylene)-phenyl, -(C<sub>0-3</sub>alkylene)-het, -(C<sub>2-3</sub>alkenylene)-phenyl, -(C<sub>2-3</sub>alkenylene)-het, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl or -N(R<sup>e</sup>)CO<sub>2</sub>R<sup>f</sup>;
- 25 R<sup>4</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-R<sup>7</sup> or -(C<sub>1-3</sub>alkylene)-R<sup>8</sup>;

- or R<sup>3</sup> and R<sup>4</sup> taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;
- 30

~~WO 2005/09031A~~153  
143~~PCT/IB2005/000597~~

- $R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy,  $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$  or  $-N(R^{12})R^{13}$ ;
- 5  $R^6$  represents  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;
- $R^7$  represents  $C_{3-8}cycloalkyl$ ,  $-S(O)_nR^9$ , phenyl, het,  $-CO_2R^6$  or  $C(O)N(R^a)R^b$ ;
- $R^8$  represents hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy, cyano,  $-N(R^a)R^b$  or  $-O-C(O)R^6$ ;
- 10  $R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}cycloalkyl$ ,  $-N(R^a)R^b$ , phenyl or het;
- $R^{10}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;
- 15  $R^{11}$  represents hydrogen, hydroxy,  $C_{1-3}alkoxy$ ,  $-N(R^a)R^b$ , phenyl, het or  $C_{3-8}cycloalkyl$ , with the proviso that  $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$  is not  $-N=CH_2$ ;
- $R^{12}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl or  $C_{1-6}$  haloalkenyl;
- 20  $R^{13}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl,  $C_{1-6}$  haloalkenyl,  $C_{3-8}cycloalkyl$ , phenyl, het,  $-(C_{1-6}alkylene)-R^{14}$ ,  $-C(O)_pR^{15}$  or  $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$ ;
- $R^{14}$  represents hydroxy,  $C_{1-3}alkoxy$ ,  $C_{1-3}haloalkoxy$ ,  $C_{3-8}cycloalkyl$ , phenyl, het or  $-N(R^a)R^b$ ;
- 25  $R^{15}$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl or  $-(C_{1-6}alkylene)-C_{1-3}alkoxy$ ;
- $R^{16}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;
- 30  $R^{17}$  represents hydrogen or  $N(R^a)R^b$ ;
- $R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents  $-(C_{0-3}alkylene)-C_{3-8}cycloalkyl$ ,  $-(C_{0-3}alkylene)-phenyl$  or  $-(C_{0-3}alkylene)-het$ , or together  $R^a$  and  $R^b$  form a 4- to 7-

~~WVO-2005/090315~~IS4.  
144~~PCT/IB2005/000597~~

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub> haloalkoxy;

5 R<sup>c</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub> alkylene)-C<sub>3-8</sub> cycloalkyl, -(C<sub>0-3</sub> alkylene)-phenyl or -(C<sub>0-3</sub> alkylene)-het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

15 where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

20 where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-8</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, C<sub>1-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkoxycarbonyl and NR<sup>a</sup>R<sup>b</sup>;

25 where C<sub>3-8</sub>cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub>haloalkenyl, hydroxy, C<sub>1-6</sub>alkoxy and C<sub>1-6</sub>haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo/


30 in the manufacture of a human or animal parasitocidal medication.

W/O 2005/090312

155  
142

PCT/IB2005/000597

15. A method of treating a ~~human~~ <sup>CLAIMS</sup> or animal parasitic infection comprising administration of a therapeutically acceptable amount of a ~~1.~~ compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof,



wherein:

- 10 R<sup>1</sup> represents phenyl or heteroaryl, optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, -S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl and pentafluorothio;
- 15 R<sup>2</sup> represents hydrogen, halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, C<sub>2-6</sub> alkynyl, C<sub>2-6</sub> haloalkynyl, -S(O)<sub>n</sub>C<sub>1-6</sub> alkyl, -S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-6</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkanoyl, optionally substituted by C<sub>1-6</sub> alkoxy, phenyl, het, -(C<sub>0-3</sub>alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub>alkylene)-C(O)NR<sup>a</sup>R<sup>b</sup> or -(C<sub>0-3</sub>alkylene)-N(R<sup>c</sup>)C(O)R<sup>d</sup>;
- 20 R<sup>3</sup> represents C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub>alkylene)-C<sub>3-6</sub> cycloalkyl, -(C<sub>1-3</sub>alkylene)-S(O)<sub>n</sub>C<sub>1-6</sub>alkyl, -(C<sub>1-3</sub>alkylene)-S(O)<sub>n</sub>C<sub>1-6</sub>haloalkyl, -(C<sub>0-3</sub>alkylene)-N(R<sup>a</sup>)R<sup>b</sup>, -(C<sub>0-3</sub>alkylene)-phenyl, -(C<sub>0-3</sub>alkylene)-het, -(C<sub>2-3</sub>alkenylene)-phenyl, -(C<sub>2-3</sub>alkenylene)-het, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl or -N(R<sup>c</sup>)CO<sub>2</sub>R<sup>d</sup>;
- 25 R<sup>4</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, -(C<sub>0-3</sub>alkylene)-R<sup>7</sup> or -(C<sub>1-3</sub>alkylene)-R<sup>8</sup>;

- or R<sup>3</sup> and R<sup>4</sup> taken together with the nitrogen and sulphur atoms to which they are attached form a 4 to 7-membered ring;
- 30

~~WO 2005/090313~~156  
143~~PCT/IB2005/000597~~

$R^5$  represents hydrogen, hydroxy, halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  haloalkenyl,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy,  $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$  or  $-N(R^{12})R^{13}$ ;

5  $R^6$  represents  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

$R^7$  represents  $C_{3-8}$ cycloalkyl,  $-S(O)_nR^9$ , phenyl, het,  $-CO_2R^8$  or  $C(O)N(R^a)R^b$ ;

$R^8$  represents hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy, cyano,  $-N(R^a)R^b$  or  $-O-C(O)R^6$ ;

10

$R^9$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{3-8}$ cycloalkyl,  $-N(R^a)R^b$ , phenyl or het;

$R^{10}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

15  $R^{11}$  represents hydrogen, hydroxy,  $C_{1-3}$ alkoxy,  $-N(R^a)R^b$ , phenyl, het or  $C_{3-8}$ cycloalkyl, with the proviso that  $-N=C(R^{10})(C_{0-5}alkylene)-R^{11}$  is not  $-N=CH_2$ ;

$R^{12}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl or  $C_{1-6}$  haloalkenyl;

20  $R^{13}$  represents hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{1-6}$  alkenyl,  $C_{1-6}$  haloalkenyl,  $C_{3-8}$ cycloalkyl, phenyl, het,  $-(C_{1-6}alkylene)-R^{14}$ ,  $-C(O)_pR^{15}$  or  $-CON(R^{16})(C_{1-6}alkylene)-R^{17}$ ;

$R^{14}$  represents hydroxy,  $C_{1-3}$ alkoxy,  $C_{1-3}$ haloalkoxy,  $C_{3-8}$ cycloalkyl, phenyl, het or  $-N(R^a)R^b$ ;

25

$R^{15}$  represents  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl or  $-(C_{1-6}alkylene)-C_{1-3}alkoxy$ ;

$R^{16}$  represents hydrogen,  $C_{1-6}$  alkyl or  $C_{1-6}$  haloalkyl;

30  $R^{17}$  represents hydrogen or  $N(R^a)R^b$ ;

$R^a$  and  $R^b$  independently represent hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl,  $C_{2-6}$  alkenyl or  $C_{2-6}$  haloalkenyl, or  $R^a$  additionally represents  $-(C_{0-3}alkylene)-C_{3-8}$  cycloalkyl,  $-(C_{0-3}alkylene)-phenyl$  or  $-(C_{0-3}alkylene)-het$ , or together  $R^a$  and  $R^b$  form a 4- to 7-

~~WO-2005/090313~~

157

~~PCT/IB2005/000597~~

144

membered ring, optionally substituted by one or more groups independently selected from halo, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy and C<sub>1-6</sub> haloalkoxy;

5 R<sup>c</sup> represents hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> haloalkenyl, -(C<sub>0-3</sub> alkylene)-C<sub>3-8</sub> cycloalkyl, -(C<sub>0-3</sub> alkylene)-phenyl or -(C<sub>0-3</sub> alkylene)-het;

n represents an integer selected from 0, 1 and 2;

p represents an integer selected from 1 and 2;

10

where het represents a four- to seven-membered heterocyclic group, which is aromatic or non-aromatic and which contains one or more heteroatoms selected from nitrogen, oxygen, sulfur and mixtures thereof;

15 where heteroaryl represents a 5 or 6 membered aromatic ring which contains 1-3 heteroatoms selected from N, O and S or 4-N atoms to form a tetrazolyl;

where both phenyl and het may be optionally substituted, where the valence allows, by one or more substituents independently selected from halo, hydroxy, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> haloalkenyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-8</sub> cycloalkyl, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> haloalkanoyl, C<sub>1-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkoxycarbonyl and NR<sup>a</sup>R<sup>b</sup>;

25 where C<sub>3-8</sub>cycloalkyl may be optionally substituted by one or more groups independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub>haloalkenyl, hydroxy, C<sub>1-6</sub>alkoxy and C<sub>1-6</sub>haloalkoxy; and

where any alkylene or alkenylene group may be optionally substituted by one or more halo.

30



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☒ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**